Traditional Japanese diet associated with less brain shrinkage in women compared to western diet, says research 
Can a drug like Ozempic help treat addictions to alcohol, opioids or other substances? 
What if flat feet were…normal? Debunking a myth about injuries 
Vaping now more common than smoking among young people – and the risks go beyond lung and brain damage 
Nike SB, Converse Roll Out 2024 US and Japan Kits, Skateboarding Shoes 
Major Victory for Bayer's Monsanto as Appeals Court Overturns $185 Million Award in Chemical Exposure Case 
Jordan Brand Wings Unveils Air Jordan I Mid Subway, Celebrating NYC's MTA Crews 
How to look after your mental health while packing up Mum or Dad’s home 
Does ejaculating often reduce your risk of prostate cancer? 
Comcast Drops Bally Sports Channels, Stops Broadcast of MLB Team Games 
Eating some chocolate really might be good for you – here’s what the research says 
Walmart Is Shutting Its Health Centers, to Discontinue Virtual Healthcare Services 
Starbucks Reports Surprise Drop in Same-Store Sales; Shares Tumble 
South Korea Pledges 5-Year Boost in Console Gaming Market Share 
Study links microplastics with human health problems – but there’s still a lot we don’t know 
KFC Shutters Over 100 Restaurants in Malaysia Over Tough Economic Conditions, Boycotts 
Adidas Unveils SS24 Paris Collection for Clay Court Season 
Germany's pharmaceutical giant, Bayer, is taking a strategic step by outsourcing the distribution of its pharmaceutical products to a third party within four key African nations: Kenya, Ethiopia, Nigeria, and Ghana.
The decision, set to take effect in May, is carefully designed to streamline the company's operations, with Bayer affirming that job impacts will be minimal.
Redistribution Strategy in Africa
According to Reuters, the team in the region, consisting of 200 specialists, will witness the reallocation of tasks related to its pharmaceutical sector. Bayer's massive crop science division, which constitutes the lion's share of its operations at 90%, will remain unaffected by this organizational tweak.
The specifics of the partner company taking over the processes—encompassing warehousing, distribution, and sales representation—remain undisclosed. This initiative primarily focuses on advanced therapies, from oncology treatments to ophthalmological care.
As the evaluation continues to determine which positions are influenced, reassurances have been provided that the number of affected employees will be kept to a minimum. As per US News, this move by Bayer bears resemblance to a similar transition by British pharma heavyweight GSK in late 2022. GSK had also adopted a third-party distribution model in Kenya, concluding its commercial activities within the country.
Legal Challenges with Roundup Litigation
Adding to Bayer's bulletin of strategic changes, the conglomerate is confronting escalating legal challenges regarding its Roundup weedkiller. Recent months have seen the German company grappling with substantial U.S. jury verdicts totaling nearly $4 billion.
A staggering $2.25 billion was awarded to a Pennsylvania plaintiff—a substantial figure presenting Bayer's most significant loss since the dawn of Roundup trials five and a half years ago. The individual who attributed their cancer diagnosis to prolonged Roundup use has captivated public and legal attention.
In the aftermath, Bayer's stock experienced a downturn as investors gauged the ramifications of over 50,000 U.S.-based claims against its Monsanto unit. Allegations claim Monsanto failed to disclose potential cancer risks associated with Roundup adequately. With the company's financial reserves under scrutiny, stakeholders are keenly awaiting Bayer's strategic response to mounting legal pressures.
Photo: Bayer Website
